PSMA放射配体治疗中转移性去势抵抗性前列腺癌肿瘤负荷的动态变化
这项回顾性双中心研究纳入331例接受PSMA放射配体治疗(PSMA RLT)的转移性去势抵抗性前列腺癌患者,用治疗后SPECT/CT测量SUVmean、SUVmax和总肿瘤体积(TTV)。中位治疗3个周期,PSA50应答率58.4%;早期应答者(第1至2周期TTV下降≥30%,n=187,56.5%)第2周期TTV下降61.3%,后续周期继续下降;轻微应答者(<30%,n=144,43.5%)各周期逐渐下降。PSA与TTV变化呈弱正相关(r=0.318,p<0.001),但43.6%患者存在PSA-TTV不一致。
要点
- PSMA RLT中约56.5%患者为早期TTV应答者,第2周期TTV下降61.3%。
- PSA与TTV变化仅弱相关(r=0.318),43.6%患者两者不一致。
- SPECT/CT动态TTV变化可用于指导PSMA RLT策略。
核心结论
- SPECT/CT测量的TTV动态变化可指导PSMA RLT策略。
研究设计与样本
- 回顾性双中心研究,纳入331例接受PSMA RLT的转移性去势抵抗性前列腺癌患者。
- 采用治疗后SPECT/CT测量SUVmean、SUVmax和TTV,计算中位百分比变化。
主要发现
- 患者接受中位3个RLT剂量,PSA50应答率为58.4%。
- 早期应答者(第1至2周期TTV下降≥30%;n=187,56.5%)第2周期TTV下降61.3%,后续周期继续下降。
- 轻微应答者(TTV下降<30%;n=144,43.5%)第2周期下降1.4%,第3周期下降26.5%,第6周期下降67.6%。
- PSA与TTV变化呈弱正相关(r=0.318,p<0.001),43.6%患者存在PSA-TTV不一致。
- 早期应答者在后续周期的肿瘤负荷下降幅度小于轻微应答者。
临床怎么用
- 可利用SPECT/CT动态监测TTV变化,早期识别应答者并调整PSMA RLT策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated quantitative changes in total metastatic tumor burden in patients with metastatic castration-resistant prostate cancer undergoing prostate-specific membrane antigen radioligand therapy (PSMA RLT) using single photon emission computed tomography/computed tomography (SPECT/CT). This retrospective two-center study included 331 patients treated with PSMA RLT. SUVmean, SUVmax, and total tumor volume (TTV) were measured using post-treatment SPECT/CT, and median percentage changes were calculated. Patients received a median of 3 RLT doses, and the prostate-specific antigen (PSA50) response rate was 58.4%. Early responders (≥30% TTV reduction between cycles 1 and 2; n = 187, 56.5%) demonstrated a 61.3% TTV reduction at cycle 2, with continued reductions in subsequent cycles. Minimal responders (<30% TTV reduction; n = 144, 43.5%) showed modest, gradual decreases across cycles (-1.4% at cycle 2, -26.5% at cycle 3, and -67.6% at cycle 6). A modest positive correlation was observed between PSA and TTV changes (r = 0.318, p < 0.001); however, 43.6% of patients exhibited PSA-TTV discordance. Early responders experienced smaller reductions in tumor burden in later cycles than minimal responders. These findings suggest that dynamic changes in TTV on SPECT/CT can be used to guide RLT strategy.
引用
- Moradpour M, Hong CM, Khan S, et al. Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT. Eur Urol Oncol. 2026. PMID: 42379902. doi:10.1016/j.euo.2026.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。